Date Filed | Type | Description |
08/15/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/11/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
07/28/2023 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
06/30/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
06/29/2023 |
25-NSE/A
| Form 25-NSE/A - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: [Amend] |
06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/05/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/05/2023 |
8-K
| Quarterly results |
03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/31/2023 |
8-K
| Quarterly results |
02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 1% stake in Entera Bio Ltd. |
11/23/2022 |
8-K
| Quarterly results |
11/18/2022 |
SC 13G/A
| CENTILLION FUND INC. reports a 8.3% stake in ENTERA BIO LTD. |
11/17/2022 |
SC 13G/A
| CENTILLION FUND INC. reports a 4.4% stake in ENTERA BIO LTD. |
11/17/2022 |
SC 13G/A
| CENTILLION FUND INC. reports a 4.4% stake in ENTERA BIO LTD. |
11/10/2022 |
SC 13G/A
| CENTILLION FUND INC. reports a 3.9% stake in ENTERA BIO LTD. |
11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/10/2022 |
8-K
| Quarterly results |
10/06/2022 |
8-K
| Quarterly results |
09/09/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
09/02/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
09/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/11/2022 |
8-K
| Quarterly results |
08/01/2022 |
8-K
| Investor presentation |
07/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
07/19/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
07/18/2022 |
8-K
| Quarterly results |
06/17/2022 |
8-K
| Quarterly results |
06/10/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
06/10/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
06/10/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
06/10/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|